Assessing Akeso (SEHK:9926) Valuation After Positive Lung Cancer Data At 2026 European Lung Cancer Congress

Akeso (SEHK:9926) has come into focus after presenting new lung cancer data at the 2026 European Lung Cancer Congress. The company updated investors on cadonilimab and ivonescimab across difficult non small cell lung cancer settings.

See our latest analysis for Akeso.

Following the ELCC updates, Akeso's HK$137.8 share price sits on the back of a 25.05% 1 month share price return and 21.62% year to date share price return. The 1 year total shareholder return of 58.48% and 3 year total shareholder return above 3x highlight how sentiment has evolved around its lung cancer portfolio.

If this kind of oncology progress has your attention, it can be worth widening the search across other healthcare names by checking out our screener of 121 healthcare AI stocks

With shares now at HK$137.8 and trading at a reported 29% intrinsic discount and 26% below the average analyst target, investors have to ask: is Akeso still mispriced, or are markets already baking in future growth?

Most Popular Narrative: 20.1% Undervalued

Akeso's most followed narrative pegs fair value at HK$172.49 per share versus the HK$137.8 last close, which puts a spotlight on what assumptions sit underneath that gap.

The company's strong R&D pipeline, including advanced bispecific antibodies and ADC candidates, provides a foundation for long-term growth, setting the stage for potential increases in net margins as products move from development to commercialization.

Read the complete narrative.

Curious what justifies that higher fair value? The narrative focuses on steep revenue expansion, a sharp swing into profitability and a richer earnings multiple than many local peers. Want the exact mix of growth, margins and valuation that underpins HK$172.49 per share? See our AI narrative and valuation for Akeso.

Result: Fair Value of HK$172.49 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are clear pressure points, including ongoing operating and EBITDA losses, as well as heavy reliance on cadonilimab and ivonescimab, that could quickly challenge this upside case.

Find out about the key risks to this Akeso narrative.

Another View: High Sales Multiple Raises the Bar

While the SWS fair value model points to Akeso trading at a 28.8% discount, the market is already attaching a rich P/S ratio of 36.2x versus 12.9x for the Hong Kong Biotechs industry and 16.8x for peers, compared with a fair ratio of 18x that the market could move toward. Does that premium leave much room if expectations slip?

Before leaning on any single fair value number, it is worth stress testing what happens if the market gradually gravitates toward that 18x fair ratio rather than rewarding current levels, and what that would imply for future upside or downside. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly divided between upside potential and high expectations, take a moment to review the numbers yourself and decide where you stand. Then weigh those views against the company’s 2 key rewards

Looking for more investment ideas?

If Akeso has sharpened your interest, do not stop here. Broaden your watchlist with other focused ideas before the next opportunity slips past you.

• Spot potential bargains early by scanning companies that appear mispriced against their fundamentals with the 234 high quality undervalued stocks
• Strengthen your income stream by reviewing businesses that currently qualify as 484 dividend fortresses
• Prioritise resilience by filtering for companies that show up in the 302 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com